Aetna Expanded Bundled Cancer Care Authorizations
The insurer is simplifying treatment plan approvals for some members as it eyes broader, plan-wide rollouts in 2027.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Is now a good time to invest in individual biotechnology stocks?
Aetna has expanded its use of the Eviti platform to offer bundled prior authorizations for cancer treatment to Medicaid members. This change aims to simplify the process for providers to secure coverage for comprehensive care plans.
Why it matters
Streamlining prior authorizations through bundled approvals can reduce administrative burdens for clinical teams, potentially accelerating access to evidence-based cancer treatment. This initiative reflects a broader shift toward simplifying complex insurance workflows.
Aetna currently processes cancer-treatment authorizations via the Eviti platform, which automatically audits clinical plans against insurance policies. This system is now applied to bundled approvals for Medicaid members, following FDA authorization of specialized treatments like Anktiva.
The players
Aetna
A major U.S. health insurance provider that facilitates access to medical care and manages coverage authorizations.
ImmunityBio
A biotechnology company that develops immunotherapy platforms for cancer, including the FDA-approved bladder cancer drug Anktiva.
Patrick Soon-Shiong
The founder of ImmunityBio who recently announced a cancer-care initiative linking the company's research with Aetna.
The details
The Eviti platform functions by mapping proposed oncology treatment plans against evidence-based clinical guidelines and specific insurance coverage policies. By allowing providers to submit comprehensive treatment paths through a single portal, the system reduces the need to file individual prior authorization requests for every component of a care plan. This move by Aetna aligns with the broader integration of automated decision-support tools in oncology.
Timeline
April 2024: Anktiva received initial FDA approval for bladder cancer.
September 1, 2026: Aetna expanded bundled approvals for Medicaid members.
October 7, 2026: ImmunityBio shares traded at $9.75.
January 6, 2027: Target FDA decision date for Anktiva label expansion.
First half 2027: Aetna plans to expand bundled approvals to more plans.
Health Landscape
The adoption of the Eviti platform represents a shift toward consolidating complex oncology treatment authorizations into single, evidence-based packets. This trend follows an industry push to reduce administrative friction as specialized, multi-drug therapies become standard of care.
If you are an Aetna member navigating cancer treatment, ask your oncologist if your treatment plan is eligible for bundled authorization to simplify your care management. Discuss with your doctor whether recent FDA-approved therapies, such as those from ImmunityBio, are applicable to your specific diagnosis.
The takeaway
Bundled authorizations aim to reduce the time spent waiting for insurance approvals by streamlining the review of entire care pathways. Patients should proactively consult with their care team about how coverage workflows might affect the timing of their specific treatment schedule.
What happens next
The FDA is scheduled to reach a decision on expanding the label for the bladder cancer drug Anktiva to include papillary-only disease on January 6, 2027.
Further reading
Learn more about the latest developments in Cancer care and treatment access.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Is now a good time to invest in individual biotechnology stocks?
